PTC THERAPEUTICS, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PTC Therapeutics reported Q3 2026 total revenue of $358M ($276M product revenue), with Sephience generating $182M (up 20% QoQ). The company raised FY2026 total revenue guidance to $1.29–1.32B (from prior) and product revenue to $960–990M, and acquired the ST-920 Fabry disease gene therapy asset from Sangamo for $111M upfront plus up to $100M in contingent regulatory milestones, with BLA submission expected Q4 2026. Cash position is $2.13B; company reports 83.5M shares outstanding and stockholders' deficit of $191M.
Why this rating
Strong revenue growth and guidance raise signal successful Sephience commercialization. $111M ST-920 acquisition is ~3.3% of market cap but strategically important pipeline addition. $2.1B cash cushions runway. However, Q3 net loss of $52M and negative equity offset gains.
Price action (we called it positive)
before filing · preread $60.00 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.